I propose to take Questions Nos. 7 and 40 together.
Officials in my Department, along with members of the steering group established to develop proposals for a new national drugs strategy are currently undertaking an extensive consultation process in regard to the new strategy. This involves 15 public consultation meetings, meetings with the various Departments and Government agencies involved, meetings with key sectoral groups and organisations working in the drugs area, along with focus groups that will include some drug users.
The public consultation meetings are being held in various locations around the country. They commenced in Dún Laoghaire on 23 April and will conclude in Croke Park on 3 June. The meetings to date have been well attended, averaging 70 to 80 people per meeting. Generally those attending have represented a good cross-section of people, from members of the public to people who are involved in drugs issues at community, voluntary, and statutory sector level. Feedback from participants at the meetings in regard to the format used and their level of satisfaction regarding being able to input has been very positive.
The full cost of advertising the public meetings is not available at this stage as only eight have been held to date. Consequently, the advertising campaign is ongoing and the details of the campaign can be subject to some change. The cost of holding the various meetings varies significantly depending on the venue, with Dublin locations generally being more expensive. Overall, the cost per venue to date is averaging at approximately €2,000.
So far, more than 120 submissions have been received from a wide variety of organisations and individuals. My Department is continuing to accept submissions and as such I expect this figure will increase during the coming weeks. I believe the public consultation process is central to the work of formulating a new strategy. It is important we hear the views of as wide a cross-section of the public as possible, young and old, to inform the overall work of developing proposals and making recommendations for an effective national drugs strategy for the period 2009-16.